The health economics of calcium and vitamin D3 for the prevention of osteoporotic hip fractures in Sweden

International Journal of Technology Assessment in Health Care

Volumn 18, Issue 4, 2002, Pages 791-807

  Willis, Michael S ^a  

^a SWEDISH INSTITUTE FOR HEALTH ECONOMICS   (Sweden)

Author keywords

Calcium; Cost effectiveness; Economics; Osteoporosis; Vitamin D

Indexed keywords

CALCIUM; COLECALCIFEROL;

AGED; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; ECONOMIC ASPECT; FAMILY HISTORY; FEMALE; HIGH RISK POPULATION; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MORTALITY; POSTMENOPAUSE OSTEOPOROSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW;

EID: 0036766979     PISSN: 02664623     EISSN: None     Source Type: Journal    
DOI: 10.1017/S0266462302000600     Document Type: Review

References (31)

1. Basavaraj S. Smoking and loss of longevity in Canada. Can J Public Health. 1993;84:341-345.
2. Chapuy M, Arlot M, Delmans P, Meunier P. Effect of calcium and cholecalciferol treatment for three years on hip fractures in elderly women. BMJ. 1994;308:1081-1082.
3. 3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-1642.
4. Cooper C. The crippling consequences of fractures and their impact on quality of life. JAMA. 1997;103:12S-19S.
5. Cummings S, Nevitt M, Browner W, et al. Risk factors for hip fracture in white women. N Engl J Med. 1995;332:767-773.
6. Dawson-Hughes B, Harris S, Krall E, Dallal G. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med. 1997;334:670-676.
7. Eddy D, Lindsay R, Cummings S, et al. Analyses of the effectiveness and cost of screening and treatment strategies for osteoporosis: A basis for development of practice guidelines. Osteoporos Int. 1998;8:1-88.
8. FASS. Läkemedel I Sverige (Pharmaceuticals in Sweden). Kungsbacka, Sweden: LINFO AB; 2001.
9. Forsén L, Søgaard A, Meyer H, Edna T-H, Kopjar B. Survival after hip fracture: Short- and long-term excess mortality according to age and gender. Osteoporos Int. 1999;10:73-78.
10. Geelhoed E, Harris A, Prince R. Cost-effectiveness analysis of hormone replacement therapy and lifestyle intervention for hip fracture. Aust J Public Health. 1994;18:153-160.
11. Jönsson B. Targeting high-risk populations. Osteoporos Int. 1998;supp. 1:S13-S16.
12. Jönsson B, Christiansen C, Johnell O, Hedbrant J. Cost-effectiveness of fracture prevention in established osteoporosis. Osteoporosis Int. 1994;5:136-142.
13. Jönsson B, Kanis J, Dawson A, Oden A, Johnell O. Effect and offset of effect of treatments for hip fracture on health outcomes. Osteoporos Int. 1999;10:193-199.
14. Kanis J, Johnell O, Oden A, et al. Risk of hip fracture according to the world health organization criteria for osteopenia and osteoporosis. Bone. 2000;27:585-590.
15. Kanis J, Johnell O, Oden A, et al. Risk of hip fracture derived from relative risks: An analysis applied to the population of Sweden. Osteoporos Int. 2000;11:120-127.
16. Kanis J, Johnell O, Oden A, et al. Long-term risk of osteoporotic fracture in Malmö. Osteoporos Int. 2000;11:669-674.
17. Kristiansen I, Johnell O. Economic and quality of life aspects of osteoporosis. In: Workshop: Treatment of osteoporosis. Läkemedelsverket (Medical Products Agency) Sweden; 1997:63-77.
18. Meunier P. Evidence-based medicine and osteoporosis: A comparison of fracture risk reduction data from osteoporosis randomised clinical trials. IJCP. 1999;53:1-7.
19. Nieves J, Komar L, Cosman F, and Lindsay R. Calcium potentiates the effect of estrogen and calcitonin on bone mass: Review and analysis. Am J Clin Nutr. 1998;67:18-24.
20. Oden A, Dawson A, Dere W, et al. Lifetime risk of hip fractures is underestimated. Osteoporos Int. 1998;8:599-603.
21. Office of Health Economics. The pros and cons of modeling in economic evaluations. Office of Health Economics Briefing. May 1997.
22. Reid I. Benefits, risks, and costs of calcium supplementation in postmenopausal women. Pharmaco Economics. 1994;5:1-4.
23. Rogers R, Powell-Griner E. Life expectancies of cigarette smokers and nonsmokers in the United States. Soc Sci Med. 1991;32:1151-1159.
24. Sonnenberg F, Beck J. Markov models in medical decision-making: A practical guide. Med Decis Making. 1993;13:322-338.
25. Statistical yearbook of Sweden. Statistics Sweden; 2000.
26. Swedish drug market II, 2000. Stockholm: Läkemedelsstatistik AB; 2000.
27. Tobaksfakta (Tobacco Facts). Nya Siffror om Svenskarnas Rökvanor (New figures on Swedish smoking habits). Available at: www.tobaksfakta.org. Accessed December 2000.
28. Tosteson A, Rosenthal D, Melton L, Weinstein M. Cost effectiveness of screening perimenopausal white women for osteoporosis: Bone densitometry and hormone replacement therapy. Ann Intern Med. 1990;113:594-603.
29. World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Tech Rep Ser 843. 1994.
30. Willis M, Odegaard K, Persson U, et al. A cost-effectiveness model of tibolone as treatment for the prevention of osteoporotic fractures in postmenopausal women in Sweden. Clin Drug Invest. 2001;21:115-127.
31. Zethraeus N, Gerdtham U-G. Estimating the costs of hip fracture and potential savings. Int J Technol Assess Health Care. 1998;14:255-267.